SuperworthGeneDx EPS WGS
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$3.64
- Latest quarter, Q2 FY26
- −$0.60
- −267% on a year earlier
- Fiscal year 2025
- −$0.75
GeneDx's earnings per share was −$3.64 over the twelve months to Jun 30, 2026, down 18300% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.60, down 267% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.75 | n/a |
| FY2024 | −$1.99 | n/a |
| FY2023 | −$7.52 | n/a |
| FY2022 | −$51.85 | n/a |
| FY2021 | −$12895.41 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.60 | −267% | −$3.64 | |
| Q1 FY26 | −$2.16 | n/a | −$2.68 | |
| Q4 FY25 | −$0.61 | −405% | −$0.75 | |
| Q3 FY25 | −$0.27 | n/a | $0.06 | |
| Q2 FY25 | $0.36 | n/a | $0.02 | |
| Q1 FY25 | −$0.23 | n/a | −$1.44 | |
| Q4 FY24 | $0.20 | n/a | −$1.99 | |
| Q3 FY24 | −$0.31 | n/a | −$3.19 | |
| Q2 FY24 | −$1.10 | n/a | −$4.52 | |
| Q1 FY24 | −$0.78 | n/a | −$5.26 | |
| Q4 FY23 | −$1.00 | n/a | −$7.52 | |
| Q3 FY23 | −$1.64 | n/a | −$32.89 |
Against its peers
Companies in Medical - Care Facilities nearest GeneDx's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| WGSGeneDx | −$3.64 | −18300% a year |
| ARDTArdent Health | $0.55 | −70% a year |
| HCSGHealthcare Services | $1.72 | +176% a year |
| PNTGPennant | $0.90 | +15% a year |
| USPHU S Physical Therapy | $0.88 | −63% a year |
| PGNYProgyny | $0.92 | +56% a year |
| ADUSAddus HomeCare | $5.70 | +26% a year |
| MDPediatrix Medical | $2.09 | +62% a year |
| OMDAOmada Health | $0.06 | |
| PRVAPrivia Health | $0.21 | +91% a year |
| AVAHAveanna Healthcare | $1.23 | +1267% a year |
| Peer median | $0.91 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on GeneDx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.